ArticleCurrent neuropharmacology2017
Aripiprazole, A Drug that Displays Partial Agonism and Functional Selectivity.
Article in Current neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 1 synthesis or guideline pooled it, 111 citations in OpenAlex.
- Reversibility of Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis.Frontiers in endocrinology · 2021Pooled it
- Clinical insight in schizophrenia: Time-specific associations with symptoms, cognition and antipsychotic mechanisms.Schizophrenia research. Cognition · 2027Article
- A preliminary cross-sectional study of bipolarity and primary pharmacotherapy in long-term stable patients with major depressive disorder.International journal of bipolar disorders · 2026Article
- Dissociation between the dynamics of symptom scores and network metrics in psychosis treatment: a proof-of-concept study using network intervention analysis.Psychopharmacology · 2026Article
- Pharmacotherapeutic Options in Drug-Resistant Bipolar Depression: From Molecular Mechanisms to Rational Polypharmacotherapy.Biomedicines · 2026Review
- Genotype epigenome phenotype integration reveals peripheral immune contributions to type I bipolar disorder.Nature communications · 2026Article
- Antipsychotic Drugs and the Risk of Diabetic Complications: A Systematic Review of Observational Studies.Journal of clinical medicine · 2026Review
- A structural overview of G-protein-coupled receptors in neurological disorders.Acta pharmacologica Sinica · 2026Review
- Functional Brain Network Abnormalities and Aripiprazole's Modulatory Effects in Pediatric Tic Disorder.Brain and behavior · 2026Article
- Genetic Variations in the Dopaminergic Signaling Pathways and Their Implications for Antipsychotics Pharmacogenetics.Journal of molecular neuroscience : MN · 2026Review
- Harnessing pyroptosis to restrain melanoma through aripiprazole.Apoptosis : an international journal on programmed cell death · 2026Article
- Pharmacokinetics, efficacy, and safety of a novel aripiprazole microsphere-based long-acting injectable formulation for schizophrenia: A multicenter, randomized controlled trial.Journal of pharmaceutical analysis · 2026Article
- Diazepam combined with aripiprazole in the treatment of a catatonic stupor patient with venous thrombosis: a case report.Frontiers in psychiatry · 2026Article
- Article
- Oral intake of aripiprazole compromises male fertility in Drosophila.Biology direct · 2025Article
- D2 receptor activation modulates NMDA receptor antagonist-enhanced high-frequency oscillations in the olfactory bulb of freely moving rats.Psychopharmacology · 2025Article
- Pharmacological Insights into Optimal Dosing in Burning Mouth Syndrome: A Narrative Review of the Non-Linear Actions of Amitriptyline and Aripiprazole.Journal of clinical medicine · 2025Review
- Case series of aripiprazole monotherapy in bipolar disorder with delayed sleep-wake phase syndrome.BMC psychiatry · 2025Article
- The Role of GCH1 Deficiency and Tetrahydrobiopterin in Mental Health.International journal of molecular sciences · 2025Article
- Effects of Risperidone and Aripiprazole Antipsychotic Drugs on Behavioral Changes and the Expression Levels of DRD2, HTR2A, AKT1, and CACNA1C Genes in the Hippocampus of a Ketamine-induced Schizophrenia-like Rat Model.Journal of molecular neuroscience : MN · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe treatment of schizophrenia is challenging due to the wide range of symptoms (positive, negative, cognitive) associated with the disease. Typical antipsychotics that antagonize D2 receptors are effective in treating positive symptoms, but extrapyramidal side-effects (EPS) are a common occurrence. Atypical antipsychotics targeting 5-HT2A and D2 receptors are more effective at treating cognitive and negative symptoms compared to typical antipsychotics, but these drugs also result in side-effects such as metabolic syndromes.
objectiveTo identify evidence in the literature that elucidates the pharmacological profile of aripiprazole.s.
methodsWe searched PubMed for peer reviewed articles on aripiprazole and its clinical efficacy, side-effects, pharmacology, and effects in animal models of schizophrenia symptoms.
resultsAripiprazole is a newer atypical antipsychotic that displays a unique pharmacological profile, including partial D2 agonism and functionally selective properties. Aripiprazole is effective at treating the positive symptoms of schizophrenia and has the potential to treat negative and cognitive symptoms at least as well as other atypical antipsychotics. The drug has a favorable side-effect profile and has a low propensity to result in EPS or metabolic syndromes. Animal models of schizophrenia have been used to determine the efficacy of aripiprazole in symptom management. In these instances, aripiprazole resulted in the reversal of deficits in extinction, pre-pulse inhibition, and social withdrawal. Because aripiprazole requires a greater than 90% occupancy rate at D2 receptors to be clinically active and does not produce EPS, this suggests a functionally selective effect on intracellular signaling pathways.
conclusionA combination of factors such as dopamine system stabilization via partial agonism, functional selectivity at D2 receptors, and serotonin-dopamine system interaction may contribute to the ability of aripiprazole to successfully manage schizophrenia symptoms. This review examines these mechanisms of action to further clarify the pharmacological actions of aripiprazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.